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Preference studies are becoming increasingly important within the medical product decision-making
context. Currently, there is limited understanding of the range of methods to gain insights into patient
preferences. We developed a compendium and taxonomy of preference exploration (qualitative) and
elicitation (quantitative) methods by conducting a systematic literature review to identify these
methods. This review was followed by analyzing prior preference method reviews, to cross-validate our
results, and consulting intercontinental experts, to confirm our outcomes. This resulted in the
identification of 32 unique preference methods. The developed compendium and taxonomy can serve as
an important resource for assessing these methods and helping to determine which are most appropriate
for different research questions at varying points in the medical product lifecycle.
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There is an emerging consensus that the patient
perspectiveshouldbe incorporatedwithindecisions
in the medical product lifecycle (MPLC; see Glossary)
[1–4], where the medical product lifecycle in this
study is defined as the lifecycles of drugs, biologics
and medical devices. Broadly encouraging the in-
volvement of patients has, therefore, become in-
creasingly important [5,6]. Taking the patient voice
into consideration has notonlybecome increasingly
important for companies that develop new medical
products but also for the authorities that assess,
regulate and decide which products are effective,
safe, well-tolerated and cost-effective [7–16].
To incorporate the patient voice, patient
preferences need to be explicitly explored or1324 www.drugdiscoverytoday.com
1359-6446/ã 2019 The Authors. Puelicited through revealed- or stated-preference
methods. In this paper, preference exploration
methods are defined as qualitative methods that
collect descriptive data through participant or
phenomenon observation, examining the sub-
jective experiences and decisions made by
participants. Elicitation methods are defined as
quantitative methods collecting quantifiable
data for hypothesis testing and other statistical
analyses. Whereas the use of revealed-prefer-
ence methods still represents a methodological
challenge in health, many different methods
exist to assess stated preferences of patients
[17,18]. An up-to-date compendium of different
stated-preference methods to explore or elicit
patient preferences within the MPLC is missing.blished by Elsevier Ltd. This is an open access article under the CC BY-There have been few publications on what
methods can be used to assess patient prefer-
ences in a scientific way, in the context of the
MPLC specifically. In 2001, Ryan et al. [19] pro-
vided an overview of methods known at the
time for eliciting public preferences for health-
care. In 2015, the Medical Device Innovation
Consortium (MDIC) developed an overview of
different preference elicitation methods as part
of their framework on incorporation of patient
preferences into regulatory assessments of
medical devices [20]. Although both publica-
tions made useful contributions, the study from
Ryan et al. [19] does not reflect methods de-
veloped since 2001, and the study from the
MDIC [20] did not include preference explora-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
https://doi.org/10.1016/j.drudis.2019.05.001
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identifying preference elicitation methods.
Therefore, the aim of our study was to develop
an up-to-date compendium and taxonomy of
exploration and elicitation preference methods
within the MPLC context. This will be an im-
portant step to further drive the incorporation of
patient preferences forward, in addition to the
study of van Overbeeke et al. [6], and in de-
veloping guidance on when and how to assess
patient preferences scientifically in the context
of decision-making in the MPLC.
Compendium of preference methods
A systematic literature review was conducted,
followed by an analysis of prior reviews by Ryan
et al. [19] and from the MDIC [20] and expert
consultations with international preference
experts, to identify all potential preference ex-
ploration and elicitation methods within the
context of the MPLC. In this paper, a broad defi-
nition of a preference method was used: any
method that enabled us to gain insight into a
patient’s relative desirability or acceptability of
specified alternatives; or choices among treat-
ment alternatives or outcomes; or other attributes
that differ among alternative health interventions
[7]. Ultimately, 208 papers were analyzed during
the systematic literature review to identify pref-
erenceexplorationandelicitationmethodswithin
the context of the MPLC. More information about
the approach used in the systematic literatureTABLE 1
Overview of identified methods
Method Description 
Exploration methods
Citizens’ juriesb Group of individuals d
Complaints
proceduresb
Method in which stak
Concept mappingb Method that utilizes sm
respondent is given e
Delphi methoda,b Structured, iterative fo
questionnaires with th
from the prior round 
Dyadic interviewa,b Method that utilizes tw
interviewer to identify
Focus groupa,b Method that utilizes a
identify how a produc
In depth – individual
interviewa,b
Interview technique th
on a particular topic or
limited amount of que
based on the respons
Nominal group
techniqueb
Method that utilizes a 
members of the group
Public meetingsb Method to gain public 
voice their responses
(Semi-)structured
individual interviewa,b
Interview technique th
interviewee says in a s
to an interview guidereview is provided in Appendix A.1 (see Supple-
mentary material online). An alphabetical over-
view of all reviewed full-text papers is listed in
Appendix B (see supplementary material online).
We identified 19 different methods: five ex-
ploration methods and 14 elicitation methods,
in the systematic literature review. The most
frequently cited exploration methods included
focus groups (n = 29, 13.9%) and (semi-)struc-
tured individual interviews (n = 47, 22.6%),
whereas most cited elicitation method papers
included discrete choice experiments (n = 57,
27.4%) and the visual analog scale (n = 12, 5.8%).
Contingent valuation (n = 11, 5.3%), standard
gamble (n = 11, 5.3%) and time trade-off (n = 11,
5.3%) were also frequently included in the an-
alyzed papers. Four studies included best–worst
scaling type 1,2 (n = 4, 2%).
Through the analysis of the preference
method reviews of Ryan et al. [19] and the MDIC
[20], and after condensing several of these
methods, we identified 23 preference explora-
tion and elicitation methods. This selection in-
cluded nine preference exploration and 14
elicitation methods. From these 23 preference
methods, 13 methods were also identified in our
systematic literature review (56%). The expert
consultations confirmed the methods identified
in the systematic literature review and in the
analysis of prior preference method reviews.
Also, consensus was reached on including four
additional elicitation methods. The expert con-iscussing issues on the basis of evidence provided by
eholders can register complaints to be investigated b
all groups of participants responding to various topics
qual opportunity to express their opinions and addres
recasting method involving a panel of experts who pro
e opportunity to revise their responses when the ano
is revealed
o participants in a single interview, responding to open
 how a product, service or opportunity is perceived
 group of interacting individuals that provide informa
t, service or opportunity is perceived
at allows for an intensive discussion with one interviewe
 theme, to gain a deeper understanding of this particul
stions or themes are prepared by the interviewer, and
e of the interviewee
group process that involves making decisions by vote a
opinions on particular issues by allowing general memb
at allows new ideas to be brought up during the int
emi-structured setting, whereas in the structured settin
 and does not ask questions based on the response osultations also resulted in the exclusion of
methods focusing on scale-related (e.g., Likert
scales) or decision-making framework-related (e.
g., multicriteria decision analysis) techniques,
because these techniques were regarded as
inconsistent with our definition of a preference
method. As described above, we identified 19
methods through the systematic literature re-
view, the 23 methods through the analysis of
previously conducted reviews and the four ad-
ditional methods via expert consultations. In
total, 32 unique preference methods were
identified: ten exploration and 22 elicitation
methods. Table 1 summarizes and briefly
describes these methods.
Taxonomy of preference methods
There are many ways to group preference
methods. In this study, we grouped the identi-
fied methods according to their manner of data
collection and the similarities in their method of
analysis. This grouping was not intended to be a
formal lexicon but primarily served as a taxon-
omy to organize results and to develop a
compendium of preference exploration and
elicitation methods. Preference exploration
methods can be grouped according to the
number of participants the method utilizes in
one session (Fig. 1). (Semi-)structured individual
interviews, in-depth interviews and complaints
procedures use interviews with one participant
(n = 1) in a single setting or session. The DelphiRefs
 two trained moderators [24,25]
y experts [26,27]
 or issues, while ensuring each
s other group dynamic issues
[28,29]
vide anonymous responses to
nymous summary of response
[30,31]
-ended questions asked by an [32,33]
tion about a specific issue to [34,35]
e to explore their perspectives
ar topic or theme. Often only a
 the rest of the questions are
[36,37]
nd ranking responses given by [38,39]
ers of the public to attend and [40,41]
erview as a result of what the
g the interviewer strictly sticks
f the interviewee
[42,43]
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TABLE 1 (Continued )
Method Description Refs
Elicitation methods
Adaptive conjoint
analysisa
Method similar to regular conjoint analysis, but with adaptive conjoint choice tasks based on the earlier
choices made within the survey, in theory allowing the survey to focus attention on those attributes or levels
of those attributes that have the most influence on the choices of that individual. Unlike discrete choice
experiments this method is founded in the theory of conjoint measurement (CM), which is more focused on
the behavior of number systems instead of the behavior of human preferences
[44,45,81]
Allocation of pointsb Method that involves asking respondents to rate their conditions on scales, while knowing the weights which
they attach to different criteria, indicating the relative importance of particular areas of their lives
[46,47]
Analytic hierarchy
processa,b
Method in which responders assess the relative importance of pairs of attributes (treatment endpoints,
properties, criteria, items, objects, etc.) toward achieving a goal, where these responses are used to compute
a weight for each attribute
[20,48]
Best–worst scaling
(types 1, 2, 3)a,b
Involves respondents answering surveys that include lists of attributes or profiles and being asked to indicate
the best (or most appealing/important) and the worst (or least appealing/important) of them. This method
consists of three types: in type 1 a set of attributes is showed that might not reflect the characteristics of any
particular treatment, of which the respondent picks the best and worst. Type 2 involves a situation in which
the attributes collectively characterize a particular profile and the respondent chooses the best and worst. In
type 3 three or more profiles are shown and the respondent selects the best and worst profiles
[20,49,50]
Constant sum scalingc Constant sum scaling consists of a comparative scale where respondents are asked to allocate a fixed amount
(or constant sum) of points, dollars or anything among a set of objects according to a criterion
[51,52]
Contingent valuationa,b Method to determine the willingness to pay (WTP), where individuals are presented with a choice between
not having the commodity valued and having the commodity but forgoing a certain amount of money. The
money being that they are willing to forgo to have the commodity is their WTP for that commodity. WTP can
be calculated directly using a threshold or indirectly using a discrete choice experiment for example
[53,54]
Control preference
scalea
The control preferences scale (CPS) is a method to determine the degree of control a patient wants regarding
medical treatment. The preference orders are analyzed using unfolding theory to determine the distribution
of preferences in different populations and the effect of covariates on consumer preferences
[55–57]
Discrete choice
experimenta,b
Method that utilizes an attribute-based measure of benefit, during which individuals are offered a series of
hypothetical choice situations (i.e., choice sets), from which they are asked to choose between two or more
profiles. There are numerous variants of discrete choice experiments. In contrast to conjoint analysis, this
method relies on a theory of the behavior of human preferences [for example random utility theory (RUM)]
[58,59,60,81]
Measure of valueb Method used to identify the optimal bundle of services to be provided given resource constraints. Individuals
are asked to allocate a fixed amount of resources between different services. These allocations are analyzed
to identify the trade-offs individuals make
[61]
Outcome prioritization
toola
Instrument that allows participants to prioritize outcomes making use of a specific tool according to the
‘trade-off ’ principle, implying that they are willing to compromise on the less important outcomes
[62]
Person trade-offa,b An extension of the time trade-off. With person trade-off an individual evaluates the health effects of
interventions using persons (instead of time) as the equilibrating mechanism
[63,64]
(Probabilistic)
threshold techniquea,b
Method that determines the maximal change in one attribute respondents are willing to accept to achieve a
given change in another attribute
[20,65]
Q-methodologyc Method that uses a specially designed response grid to present respondents with a set of statements and
asking them to order, usually based on the extent to which they agree with them
[66,67]
Qualitative
discriminant processb
Method that involves a scoring and ranking process based on decision analysis technique, involving the
definition of options in terms of qualitative categories, then deriving a numeric point estimate and finally
solving a maximization problem with given constraints
[68]
Repertory grid
methoda
Method used for eliciting personal constructs (i.e., what people think about a given topic). To identify
preferences overlapping and rating techniques are used
[69,70]
Self-explicated
conjointc
Method that asks explicitly about the preference for each attribute rather than the preference of several [71]
Standard gamblea,b Method in which respondents are asked to choose between a certain outcome and a gamble that might
result in either a better outcome with a probability P or a worse outcome than the original with a probability
1-P
[72,73]
Starting known
efficacya
Method similar to (probabilistic) threshold techniques, but with a specific known starting point. This method
is specifically used within the context of the medical product lifecycle
[74]
Swing weightingb Method for setting the weights in which a decision-relevant range is specified for each attribute, and the
impact of ‘swinging’ the attribute through that entire range of values is assigned a weight relative to the
impact of swinging the attribute with the largest weight
[19,20]
Test trade-offc Method that can be regarded as an extension of the time trade-off that is specifically used to evaluate a new
biomarker by using risks (instead of time) as the equilibrating mechanism
[75,76]
Time trade-offa,b Method that presents individuals with a choice between living for a period in a specified, but less than
perfect, state versus having a healthier life for a period of time, where time is varied until the respondent is
indifferent to the alternatives
[20,77,78]
Visual analog scalea,b A self-reporting instrument consisting of a line of predetermined length that separates extreme boundaries
of the phenomenon being measured
[79,80]
In total 32 unique methods were identified.
a Identified in systematic review (19 methods).
b Identified through analysis of previous preference method reviews (23 methods).
c Identified with expert consultations (4 methods).
1326 www.drugdiscoverytoday.com
Featu
res
P
ER
SP
EC
TIV
E
Drug Discovery Today Volume 24, Number 7  July 2019
Preference
exploration
Individual methods Group methods Individual/group
methods
In-depth individual
interview
(Semi-)structured
individual interview Public meetings
Delphi method
Concept mapping
Focus group
Dyadic interview
Nominal group technique
Complaints procedures Citizens’ juries
Drug Discovery Today 
FIGURE 1
Grouping of preference exploration (qualitative) methods into three groups: individual, group and individual/group methods.
Discrete choice
experiment/best-worst
scaling type 3
Best-worst scaling
Type 1,2
Adaptive conjoint
analysis
Self-explicated
conjoint
Analytic hierarchy
process
Measure of value
Allocation of points
Starting known efficacy
Time trade-off
Standard gamble
Person trade-off
Visual analog scaleConstant sum scaling
Qualitative
discriminant process
Repertory grid method
(Probabilistic) threshold
technique
Swing weighting
Outcome prioritization
tool
Contingent valuation
Control preferences
scale
Q-methodology
Test trade-off
Preference
elicitation
Discrete-choice-
based methods
Indifference
methods
Rating methodsRanking methods
Drug Discovery Today 
FIGURE 2
Grouping of preference elicitation (quantitative) methods into four groups: discrete choice based, ranking, indifference and rating methods.
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meetings, nominal group technique and citizen
juries typically direct questions to more than
one participant (n >1) in a single setting. Con-
cept mapping can employ either individual or
group settings for data collection (n 1).
Preference elicitation methods can be
grouped into four distinct groups (Fig. 2), with
methods from left to right being able to answer
a smaller subset of research questions [a discrete
choice experiment (DCE) is for example able to
provide willingness-to-pay (WTP) information
and probability scores whereas contingent val-
uation provides WTP information only]. First,
discrete choice-based methods typically exam-
ine the importance of trade-offs between attri-
butes and their alternatives through a series ofTABLE 2
Background information of identified patien
Method Frequency 
n = 19 n = 208a (%) 
Exploration methods
Delphi method 3 (1.4) 
Dyadic interview 1 (0.5) 
Focus group 29 (13.9
In depth – individual
interview
9 (4.3) 
(Semi-)structured
individual interview
47 (22.6
Elicitation methods
Adaptive conjoint
analysis
3 (1.4) 
Analytic hierarchy
process
1 (0.5) 
Best-worst scaling (types
1, 2,3)
4 (1.9) 
Contingent valuation 11 (5.3) 
Control preference scale 3 (1.4) 
Discrete choice
experiment
57 (27.4
Outcome prioritization
tool
1 (0.5) 
Person trade-off 1 (0.5) 
Repertory grid method 1 (0.5) 
Standard gamble 11 (5.3) 
Starting known efficacy 1 (0.5) 
(Probabilistic) threshold
technique
2 (1.0) 
Time trade-off 11 (5.3) 
Visual analog scale 12 (5.8) 
a Included countries per continent: Africa – Kenya, South Africa
– France, Germany, UK, Hungary, The Netherlands, Norway, S
1328 www.drugdiscoverytoday.comchoice sets that present (hypothetical) alterna-
tives. Second, ranking (or related) methods were
classified based on the use of ranking exercises
to capture the order of alternatives or attributes
within a presented set. Third, indifference
techniques are methods that vary the value of
one attribute in one of the alternatives until the
participant is indifferent, or has no preference,
between alternatives. Finally, rating (or related)
methods are methods based on their utilization
of comparative rating approaches, often allow-
ing participants to express the strength of their
preferences along a labeled scale.
Trends in the use of preference methods
With the systematic literature review, spanning
37 years of literature, we observed an overallt preference methods in the systematic review
Continents of origin St
Continents (frequency)a n =
Asia (2), North America (1) 24
Africa (1) 26
) Africa (1), Asia (2), Australia/Oceania
(3), Europe (15), North America (8)
2, 
21
30
Asia (1), Australia/Oceania (1),
Europe (3), North America (4)
32
) Africa (2), Asia (6), Australia/Oceania
(6), Europe (18), North America (15)
2, 
12
21
27
North America (3) 88
Europe (1) 22
Asia (1), Australia/Oceania (1), North
America (2)
13
Asia (2), Australia/Oceania (1), North
America (2)
29
Asia (1), North America (2) 14
) Africa (1), Asia (7), Australia/Oceania
(6), Europe (15), North America (28)
19
10
16
21
24
Europe (1) 30
Europe (1) 27
Europe (1) 25
Asia (1), Australia/Oceania (1),
Europe (2), North America (7)
34
North America (1) 20
North America (2) 42
Australia/Oceania (1), Europe (2),
North America (8)
33
Asia (2), Europe (3), North America
(7)
93
; Asia – China, Iran, Japan, Malaysia, Singapore, South Korea, Tai
pain; North America – Canada, USA.upwards trend in the number of MPLC patient
preference studies per year. The mean number
of preference studies increased from 1.1 per year
to 6.5 per year to 20.3 per year. This is for the
periods 1980–2000, 2001–2010 and 2011–2016,
respectively (Appendix C, see supplementary
material online). We also observed that our
included papers originated from all over the
world, covering five different continents (Table 2
). The majority (73%) of papers were from North
America (n = 90) and Europe (n = 62).
Analyzing the separate use of preference
exploration and elicitation methods over time,
we observed a trend of preference exploration
methods being used more frequently in recent
years. We did not consider the period 1980–
2005 because this period only included a few focusing on the medical product lifecycle
udy numbers
 208
, 107, 308
9
14, 17, 18, 43, 45, 71, 72, 84, 97, 109, 116, 119, 121,
1, 220, 222, 236, 253, 269, 282, 283, 286, 290, 294,
0, 308, 313, 317
, 41, 108, 147, 173, 191, 193, 211, 316
9, 17, 18, 21, 30, 41, 43, 57, 58, 65, 67, 87, 94, 100, 101,
0, 129, 141, 153, 162, 164, 184, 193, 198, 205, 211,
5, 217, 222, 226, 229, 230, 232, 239, 267, 268, 269,
2, 280, 284, 285, 286, 302, 306, 310, 323
, 89, 243
1
3, 180, 189, 300
, 35, 144, 148, 155, 166, 167, 180, 199, 244, 298
7, 175, 316
, 25, 26, 34, 42, 48, 57, 66, 73, 79, 80, 90, 100, 101,
9, 114, 117, 119, 122, 133, 134, 154, 155, 160, 161,
3, 166, 179, 180, 184, 192, 194, 200, 212, 213, 215,
8, 219, 222, 227, 229, 234, 238, 239, 243, 246, 247,
9, 257, 264, 266, 272, 281, 309, 311, 312, 313
4
4
5
, 42, 155, 180, 195, 200, 209, 219, 237, 277, 312
1
, 172
, 34, 78, 155, 180, 200, 209, 219, 237, 277, 318
, 115, 168, 171, 178, 195, 208, 223, 278, 281, 287, 314
wan, Thailand, Turkey; Australia/Oceania – Australia; Europe
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tages. For the period 2002–2006, 33.3% of the
papers used a preference exploration method to
gain insights into patient preferences (com-
puted as the frequency of an exploration or
elicitation method in each individual paper).
This increased to 48.8% in the period 2007–2011
and to 45.8% for 2012–2016. Among preference
exploration methods, the proportion of studies
that used focus groups increased from 23% in
the period 2002–2006 to 35% in the period
2012–2016. The proportion of (semi-)structured
individual interviews remained more or less
constant with 55% in the period 2002–2006 and
52% in the period 2012–2016, whereas in-depth
individual interviews decreased from 23% in
2002–2006 to 8% in 2012–2016. Over time, we
also observed more diversity within the group of
preference exploration methods. The Delphi
method and dyadic interviews began appearing
in 2007.
Among preference elicitation methods, we
observed that the number of papers that made
use of a discrete choice experiment increased
from 38% in 2002–2006 to 58% in 2012–2016.
Papers that included a visual analog scale de-
creased from 16% to 3%, and contingent valu-
ation showed a similar trend (17% to 9%).
Standard gamble and time trade-off showed an
upward trend, from 5% and 4% in 2002–2006 to
9% and 6% in 2012–2016, respectively. Overall,
we observed that, over time, a more diverse
group of preference elicitation methods was
used.
Comparison of sources
The results of this study were partly in line with
the results found by Ryan et al. (2001) and the
MDIC (2015) [19,20]. Fifty-six percent (13 out of
23) of methods reported by Ryan et al. [19] and/
or the MDIC [20] were identified in our sys-
tematic literature review. The differences arise
because: (i) the search in this study focused
specifically on methods to obtain patient pre-
ferences for drugs and medical devices, whereas
Ryan et al. [19] focused on public views on the
provision of healthcare; (ii) MDIC [20] excluded
preference exploration methods; and (iii) the
MDIC [20] effort did not use a systematic ap-
proach for identifying methods. The taxonomy
of preference methods proposed in this study is
also in line with results from Mt-Isa et al. [21],
Zhang et al. [22] and Gonzalez et al. [23], in
which elicitation methods were grouped by
rating, ranking and trade-off (which included
choice-based methods) techniques, although
many other ways to group these methods are
possible.Results from our study’s systematic literature
review (19 preference methods identified)
showed that most reviewed papers used focus
groups, (semi-)structured individual interviews,
discrete choice experiments or the visual analog
scale to gain insights into patient preferences.
Most of these studies were conducted in North
America or Europe. We also showed that the
mean number of patient preference studies for
drugs and medical devices increased over time.
Furthermore, this study showed that, for pref-
erence exploration and elicitation methods, a
more diverse mix of methods (exploration and
elicitation methods) was used over time to
explore or elicit preferences.
Concluding remarks
In this study we developed an up-to-date
compendium and taxonomy of preference ex-
ploration and elicitation methods in the context
of the MPLC. The systematic review (19 meth-
ods), analysis of prior conducted preference
method reviews (23 methods) and expert con-
sultations (four methods) contributed to this
compendium. In total, 32 unique methods were
identified. Preference exploration methods were
grouped in three main groups, whereas the
preference elicitation methods were grouped in
four main groups. Because choosing which
method to use will depend on the MPLC phase
and what the measured preferences are being
used for, future research might focus on deter-
mining which methods are most appropriate to
explore or elicit patient preferences, and under
what circumstances, throughout the different
phases in the MPLC. In addition, it might be of
interest for future research to focus on the
specific combinations of preference exploration
and elicitation methods used in mixed-method
studies, and the reasoning behind such study
designs.
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